| 6.2 0.19 (3.16%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.7 |
1-year : | 9 |
| Resists | First : | 6.59 |
Second : | 7.7 |
| Pivot price | 6.08 |
|||
| Supports | First : | 5.96 |
Second : | 5.57 |
| MAs | MA(5) : | 6.07 |
MA(20) : | 6.06 |
| MA(100) : | 6.99  |
MA(250) : | 7.28 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 59.5 |
D(3) : | 53 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 11.8 | Low : | 4.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NVCT ] has closed below upper band by 19.1%. Bollinger Bands are 68.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 43 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.38 - 6.4 | 6.4 - 6.43 |
| Low: | 5.95 - 5.97 | 5.97 - 6 |
| Close: | 6.15 - 6.19 | 6.19 - 6.24 |
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Thu, 16 Oct 2025
Oct 23 Posters: NXP900 — Nuvectis Pharma Presents Safety, PK, CYP and Tumor Inhibition Data at AACR 2025 - Stock Titan
Thu, 25 Sep 2025
From $14.6B J&J Deal Success: Nuvectis Pharma Adds Key Biotech Executive to Board Ahead of Phase 1b Trial - Stock Titan
Thu, 04 Sep 2025
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
Sun, 10 Aug 2025
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) stock price dropped 12% last week; retail investors would not be happy - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 39.9 (%) |
| Held by Institutions | 13.9 (%) |
| Shares Short | 988 (K) |
| Shares Short P.Month | 983 (K) |
| EPS | -1.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -63.4 % |
| Return on Equity (ttm) | -150.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -5.35 |
| PEG Ratio | 0 |
| Price to Book value | 8.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|